RxDoctor Payments DataLook up a doctor →

Lori Moyers, DO

Family Medicine · Cape Girardeau, MONPI 1023145125

Payments from drug & device makers

$21,031in general payments, 2019–2025

Across 1,195 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • AstraZeneca$2K
  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • Johnson & Johnson$917
  • Amgen$805
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$1101%
  • Food & beverage$20,56898%
  • Education$3532%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)255$4,622
AstraZeneca70$1,797
Lilly USA, LLC95$1,317
Novo Nordisk69$1,119
Johnson & Johnson45$917
Amgen59$805
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC42$608
Astellas Pharma US Inc24$556
Nestle Healthcare Nutrition Inc.29$522
Aimmune Therapeutics, Inc.21$503
GSK35$497
Amarin Pharma, Inc.35$455
Mylan Specialty L.p.17$442
Sanofi-aventis U.S. LLC21$437
Abbott21$426
Otsuka America Pharmaceutical, Inc.22$399
Boehringer Ingelheim21$396
Pfizer39$392
Merck25$386
Novartis22$359
Lundbeck LLC17$310
Sunovion Pharmaceuticals Inc.10$296
Takeda Pharmaceuticals U.S.A., Inc.22$265
Scilex Pharmaceuticals Inc.14$225
Vanda Pharmaceuticals Inc.5$208
Zyla Life Sciences, Inc.15$197
Axsome Therapeutics, Inc.8$183
Bayer11$176
Eisai Inc.10$166
Teva Pharmaceuticals USA, Inc.5$154
Phathom Pharmaceuticals, Inc.8$142
Biohaven Pharmaceutical Holding Company Ltd.7$139
Exact Sciences8$136
Xeris Pharmaceuticals, Inc.5$113
Idorsia Pharmaceuticals US Inc6$95
E.r. Squibb & Sons, L.L.C.6$85
Paratek Pharmaceuticals, Inc.5$80
Sumitomo Pharma America, Inc.5$76
Biohaven Pharmaceuticals, Inc.4$68
Avanir Pharmaceuticals, Inc.5$68
Upsher-smith Laboratories LLC4$67
Sanofi1$60
Kowa Pharmaceuticals America, Inc.4$59
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$55
Verona Pharma, Inc.3$55
Viatris Specialty LLC3$52
Dexcom, Inc.3$49
Arbor Pharmaceuticals, Inc.3$47
Boston Scientific2$43
Ardelyx, Inc.2$36
Supernus Pharmaceuticals, Inc.2$33
Aytu Biopharma, Inc.2$32
Daiichi Sankyo Inc.2$31
Averitas Pharma Inc.1$28
Seqirus USA Inc1$27
Acadia Pharmaceuticals Inc1$20
Esperion Therapeutics, Inc.1$20
Apria Healthcare LLC1$17
Protega Pharmaceutials Inc1$17
Assertio Therapeutics, Inc.2$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,031 in reported general payments places this provider in the 95th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$260,723
Medicare patients
359
Services billed
4,205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide234$232,320
MounjaroTirzepatide122$149,511
Trelegy ElliptaFluticasone/Umeclidin/Vilanter178$117,961
FarxigaDapagliflozin Propanediol123$86,661
XareltoRivaroxaban122$80,534
RexultiBrexpiprazole68$60,940
JardianceEmpagliflozin89$56,648
EliquisApixaban94$52,590
LinzessLinaclotide82$49,685
EntrestoSacubitril/Valsartan53$41,719
VraylarCariprazine Hcl25$34,754
MyrbetriqMirabegron88$33,625
RybelsusSemaglutide27$31,802
Breztri AerosphereBudesonide/Glycopyr/Formoterol43$28,841
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen737$26,862

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,119$264,122261 claims
Lilly USA, LLCMounjaro, Trulicity$1,317$170,995144 claims
GSKTrelegy Ellipta, Arexvy, Shingrix, Breo Ellipta$497$151,227292 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,797$137,393234 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Synjardy, Glyxambi$396$108,210179 claims
AbbVieLinzess, Vraylar, Creon$4,622$107,750119 claims
Johnson & JohnsonXarelto$917$80,534122 claims
Otsuka America Pharmaceutical, Inc.Rexulti$399$60,94068 claims
PfizerEliquis$392$52,59094 claims
NovartisEntresto$359$41,71953 claims
MerckBelsomra, Januvia, Dulera$386$34,69778 claims
Astellas Pharma US IncMyrbetriq$556$33,62588 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Cape Girardeau

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →